We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+27.29%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.31B
AUM Growth
+$931M
Cap. Flow
+$3.42M
Cap. Flow %
0.05%
Top 10 Hldgs %
41.19%
Holding
233
New
22
Increased
88
Reduced
44
Closed
17

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$66M
2
CRL icon
Charles River Laboratories
CRL
+$38M
3
WVE icon
Wave Life Sciences
WVE
+$20.8M
4
ABT icon
Abbott
ABT
+$19M
5
PACB icon
Pacific Biosciences
PACB
+$17.1M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$108M
2
ALDR
Alder Biopharmaceuticals
ALDR
+$84.7M
3
BOLD
Audentes Therapeutics, Inc
BOLD
+$53.2M
4
GILD icon
Gilead Sciences
GILD
+$35.4M
5
TDOC icon
Teladoc Health
TDOC
+$29.6M

Sector Composition

Rank Sector Weight
1 Healthcare 95.59%
2 Industrials 0.45%
3 Technology 0.42%
4 Communication Services 0.09%
5 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RGNX icon
151
Regenxbio
RGNX
$623M
$856K 0.01%
20,900
-12,800
-38% -$506K
AUTL
152
Autolus Therapeutics
AUTL
$386M
$821K 0.01%
62,200
+27,600
+80% +$361K
MCK icon
153
McKesson
MCK
$98.5B
$812K 0.01%
5,874
-50
-0.8% -$7.07K
CLVS
154
DELISTED
Clovis Oncology, Inc.
CLVS
$760K 0.01%
+72,900
New +$530K
BOLD
155
DELISTED
Audentes Therapeutics, Inc
BOLD
$736K 0.01%
12,300
-1,417,304
-99% -$53.2M
FAST icon
156
Fastenal
FAST
$54B
$713K 0.01%
38,598
– –
SWKS icon
157
Skyworks Solutions
SWKS
$9.06B
$689K 0.01%
5,700
– –
VAR
158
DELISTED
Varian Medical Systems, Inc.
VAR
$582K 0.01%
4,100
– –
ALV icon
159
Autoliv
ALV
$8.6B
$574K 0.01%
6,800
– –
DPZ icon
160
Domino's
DPZ
$11B
$558K 0.01%
1,900
– –
MTD icon
161
Mettler-Toledo International
MTD
$26.8B
$555K 0.01%
700
– –
GILD icon
162
Gilead Sciences
GILD
$161B
$552K 0.01%
8,500
-543,100
-98% -$35.4M
HTHT icon
163
Huazhu Hotels Group
HTHT
$12.4B
$541K 0.01%
13,500
– –
ST icon
164
Sensata Technologies
ST
$6.65B
$533K 0.01%
9,900
– –
CBPO
165
DELISTED
China Biologic Products Holdings, Inc.
CBPO
$524K 0.01%
4,500
– –
JD icon
166
JD.com
JD
$40.8B
$518K 0.01%
14,700
– –
EA icon
167
Electronic Arts
EA
$52.4B
$516K 0.01%
4,800
– –
ENTG icon
168
Entegris
ENTG
$19.7B
$516K 0.01%
10,300
– –
BF.B icon
169
Brown-Forman Class B
BF.B
$12B
$514K 0.01%
7,600
– –
MTB icon
170
M&T Bank
MTB
$36.2B
$509K 0.01%
3,000
– –
IPGP icon
171
IPG Photonics
IPGP
$3.89B
$507K 0.01%
3,500
– –
GGG icon
172
Graco
GGG
$12.9B
$504K 0.01%
9,700
– –
WSO icon
173
Watsco Inc
WSO
$14.9B
$504K 0.01%
2,800
– –
MKTX icon
174
MarketAxess Holdings
MKTX
$4.15B
$501K 0.01%
1,322
– –
AVNT icon
175
Avient
AVNT
$3.45B
$500K 0.01%
13,600
– –
5 6
7
8 9

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q4 2019 Portfolio in Review

As of Q4 2019, Bellevue Group held 233 positions worth $6.31B, up 17% from $5.38B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Bellevue Group's Q4 2019 filing shows 22 new, 88 increased, 44 reduced and 17 closed positions. Its largest new stake was Molecular Templates, Inc.: 86,379 shares worth $18.1M. The largest sale was Celgene Corp, an estimated $108M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q4 2019 buy was Molecular Templates, Inc.: 86,379 shares worth $18.1M.
  • Bellevue Group added most to Bristol-Myers Squibb in Q4 2019, an estimated $66M increase.
  • Bellevue Group's biggest Q4 2019 reduction was Audentes Therapeutics, Inc, cutting an estimated $53.2M.
  • Bellevue Group fully exited Celgene Corp in Q4 2019, selling an estimated $108M.
  • Bellevue Group's ten largest holdings make up 41% of its $6.31B portfolio in Q4 2019.
  • Bellevue Group opened 22 new positions and closed 17 in Q4 2019.
  • Bellevue Group's portfolio value rose 17% quarter-over-quarter to $6.31B.

Based on Bellevue Group's 13F filing for Q4 2019, filed 14 Feb 2020.